Breaking News Instant updates and real-time market news.

AGIO

Agios Pharmaceuticals

$40.94 /

+0.19 (+0.47%)

09:58
11/17/21
11/17
09:58
11/17/21
09:58

Agios Pharmaceuticals to hold a virtual investor day

Virtual Investor Day to discuss the Company's research and development pipeline, as well as provide additional insights into the commercial launch strategy and expectations for Mitapivat in PK deficiency will be held on November 17 at 2 pm. Webcast Link

  • 17

    Feb

OTHER BREAKING NEWS FROM THE FLY

Conference/Events
EDAP TMS to hold an expert panel » 23:57
09/28/22
09/28
23:57
09/28/22
23:57
EDAP

EDAP TMS

$8.08 /

+0.08 (+1.00%)

CEO Oczachowski hosts an…

CEO Oczachowski hosts an Urology Expert Panel and live Focal One technology demonstration in New York on September 29 at 8 am. Webcast Link

ShowHide Related Items >><<
EDAP EDAP TMS
$8.08 /

+0.08 (+1.00%)

EDAP EDAP TMS
$8.08 /

+0.08 (+1.00%)

05/18/22 Piper Sandler
EDAP TMS price target lowered to $11 from $13 at Piper Sandler
11/19/21 B. Riley
EDAP TMS price target lowered to $10 from $13 at B. Riley
EDAP EDAP TMS
$8.08 /

+0.08 (+1.00%)

  • 23
    Sep
EDAP EDAP TMS
$8.08 /

+0.08 (+1.00%)

Conference/Events
Vulcan Materials to hold virtual investor day » 23:47
09/28/22
09/28
23:47
09/28/22
23:47
VMC

Vulcan Materials

$156.15 /

+3.91 (+2.57%)

Virtual Investor Day to…

Virtual Investor Day to be held on September 29 at 8 am. Webcast Link

ShowHide Related Items >><<
VMC Vulcan Materials
$156.15 /

+3.91 (+2.57%)

VMC Vulcan Materials
$156.15 /

+3.91 (+2.57%)

09/22/22 JPMorgan
Vulcan Materials price target raised to $185 from $170 at JPMorgan
09/21/22 Barclays
Barclays sees over 45% potential upside in Vulcan shares
09/01/22 Vertical Research
Vulcan Materials upgraded to Buy from Hold at Vertical Research
08/18/22 Raymond James
Vulcan Materials assumed with Outperform from Market Perform at Raymond James
VMC Vulcan Materials
$156.15 /

+3.91 (+2.57%)

VMC Vulcan Materials
$156.15 /

+3.91 (+2.57%)

Hot Stocks
Guidewire announces $200M accelerated share buyback program » 20:28
09/28/22
09/28
20:28
09/28/22
20:28
GWRE

Guidewire

$61.98 /

+0.24 (+0.39%)

Guidewire "announced…

Guidewire "announced that as part of its previously announced $400M share repurchase authorization, the company has entered into an accelerated share repurchase agreement with Morgan Stanley & Co. LLC to repurchase an aggregate of $200M of Guidewire's outstanding shares of common stock."

ShowHide Related Items >><<
GWRE Guidewire
$61.98 /

+0.24 (+0.39%)

GWRE Guidewire
$61.98 /

+0.24 (+0.39%)

09/12/22 Citi
Guidewire price target lowered to $79 from $88 at Citi
09/08/22 Baird
Guidewire price target lowered to $81 from $99 at Baird
09/07/22 JMP Securities
Guidewire price target lowered to $95 from $110 at JMP Securities
09/07/22 RBC Capital
Guidewire price target lowered to $100 from $125 at RBC Capital
GWRE Guidewire
$61.98 /

+0.24 (+0.39%)

GWRE Guidewire
$61.98 /

+0.24 (+0.39%)

Initiation
Kindred Group initiated with a Hold at Jefferies » 19:28
09/28/22
09/28
19:28
09/28/22
19:28
KNDGF

Kindred Group

$5.20 /

-2.8 (-35.00%)

Jefferies analyst James…

Jefferies analyst James Wheatcroft initiated coverage of Kindred Group with a Hold rating and SEK 90 price target as part of a broader research note on Europe Gaming. The analyst states that the temporary exit from the Netherlands and tough comps should subdue the stock for some time, and he recommends a neutral stance given limited catalysts in the short to medium term.

ShowHide Related Items >><<
KNDGF Kindred Group
$5.20 /

-2.8 (-35.00%)

KNDGF Kindred Group
$5.20 /

-2.8 (-35.00%)

08/09/22 BofA
Kindred Group initiated with Underperform, SEK 88 target at BofA
08/09/22 BofA
Kindred Group initiated with an Underperform at BofA
07/28/22 Berenberg
Kindred Group price target lowered to SEK 113 from SEK 123 at Berenberg
04/29/22 Deutsche Bank
Kindred Group price target lowered to SEK 123 from SEK 127 at Deutsche Bank
Initiation
Kambi Group initiated with a Buy at Jefferies » 19:25
09/28/22
09/28
19:25
09/28/22
19:25
KMBIF

Kambi Group

$14.73 /

+ (+0.00%)

Jefferies analyst James…

Jefferies analyst James Wheatcroft initiated coverage of Kambi Group with a Buy rating and SEK 220 price target as part of a broader research note on Europe Gaming. The analyst cites the company's 20% share in the burgeoning U.S. sports betting market, also citing catalysts for Kambi over the next year that include a re-rating as material new contracts further endorse its proof of concept as well as an "earnings progression derived from contract renewals".

ShowHide Related Items >><<
KMBIF Kambi Group
$14.73 /

+ (+0.00%)

04/14/22 Pareto
Kambi Group downgraded to Hold from Buy at Pareto
01/07/22 Berenberg
Kambi Group initiated with a Buy at Berenberg
01/07/22 Berenberg
Kambi Group initiated with a Buy at Berenberg
Initiation
Evolution AB initiated with a Buy at Jefferies » 19:23
09/28/22
09/28
19:23
09/28/22
19:23
EVVTY

Evolution AB

$82.30 /

+3.31 (+4.19%)

Jefferies analyst James…

Jefferies analyst James Wheatcroft initiated coverage of Evolution AB with a Buy rating and SEK 1,260 price target as part of a broader research note on Europe Gaming. The analyst contends that only 50% of the live casino opportunity is currently priced in for Evolution, also noting that the stock's current valuation multiples are low versus history. Wheatcroft further states that best on its cash reserve, further buybacks and M&A are possible for the company.

ShowHide Related Items >><<
EVVTY Evolution AB
$82.30 /

+3.31 (+4.19%)

08/08/22 Deutsche Bank
Evolution AB price target lowered to SEK 1,005 from SEK 1,175 at Deutsche Bank
07/28/22 Berenberg
Evolution AB price target lowered to SEK 1,170 from SEK 1,230 at Berenberg
04/29/22 Morgan Stanley
Evolution AB price target raised to SEK 1,780 from SEK 1,750 at Morgan Stanley
04/29/22 Deutsche Bank
Evolution AB price target lowered to SEK 1,175 from SEK 1,220 at Deutsche Bank
Hot Stocks
Avita Medical names James Corbett CEO » 19:09
09/28/22
09/28
19:09
09/28/22
19:09
RCEL

Avita Medical

$5.65 /

+0.39 (+7.41%)

Avita Medical announced…

Avita Medical announced the appointment of James Corbett as Chief Executive Officer, effective immediately. Corbett, who has served as a non-executive member of the Board of Directors, will continue as an executive member of the Board of Directors of AVITA Medical, Inc. Corbett, has nearly 40 years of experience in the Life Sciences field, having served as CEO of multiple publicly traded companies, including: Microtherapeutics Inc., ev3 Inc and Alphatec Spine. "Jim is an experienced strategist with significant commercial expertise that positions him well to lead AVITA Medical through its next stage of growth and beyond," said Lou Panaccio, Chairman of the Board of AVITA Medical. "Having run a thorough process utilizing a leading executive search firm, I am confident that Jim is the right leader for the Company at this time." Corbett will succeed Dr. Michael Perry, who has served as Executive Director and Chief Executive Officer of the Company since June 2017.

ShowHide Related Items >><<
RCEL Avita Medical
$5.65 /

+0.39 (+7.41%)

RCEL Avita Medical
$5.65 /

+0.39 (+7.41%)

09/12/22 Piper Sandler
Avita Medical data for stable vitiligo treatment excellent, says Piper Sandler
03/01/22 BTIG
Avita Medical price target lowered to $21 from $37 at BTIG
03/01/22 Piper Sandler
Avita Medical price target lowered to $15 from $23 at Piper Sandler
RCEL Avita Medical
$5.65 /

+0.39 (+7.41%)

Periodicals
BP lays off most contractors at Toledo plant after fire, Reuters says » 18:53
09/28/22
09/28
18:53
09/28/22
18:53
BP

BP

$28.57 /

+1.005 (+3.65%)

, CVE

Cenovus Energy

$15.61 /

+0.77 (+5.19%)

BP (BP) laid off most…

BP (BP) laid off most contractors at its Toledo, Ohio refinery that it operates jointly with Cenovus Energy (CVE), suggesting that the facility will see a prolonged shutdown following last week's fire, Reuters' Laura Sanicola reports, citing sources familiar with the matter. The explosion at the plant killed two steelworkers, the author notes. Reference Link

ShowHide Related Items >><<
CVE Cenovus Energy
$15.61 /

+0.77 (+5.19%)

BP BP
$28.57 /

+1.005 (+3.65%)

BP BP
$28.57 /

+1.005 (+3.65%)

09/26/22 JPMorgan
BP downgraded to Neutral from Overweight at JPMorgan
09/12/22 Piper Sandler
BP price target raised to $47 from $44 at Piper Sandler
08/17/22 Morgan Stanley
BP price target raised to 566 GBp from 540 GBp at Morgan Stanley
08/08/22 Berenberg
BP price target lowered to 500 GBp from 510 GBp at Berenberg
CVE Cenovus Energy
$15.61 /

+0.77 (+5.19%)

08/10/22 Credit Suisse
Cenovus Energy assumed with an Outperform at Credit Suisse
07/18/22 National Bank
Cenovus Energy price target lowered to C$38 from C$41 at National Bank
06/16/22 National Bank
Cenovus Energy price target raised to C$41 from C$35 at National Bank
06/09/22 Credit Suisse
Cenovus Energy price target raised to C$37 from C$32 at Credit Suisse
CVE Cenovus Energy
$15.61 /

+0.77 (+5.19%)

BP BP
$28.57 /

+1.005 (+3.65%)

BP BP
$28.57 /

+1.005 (+3.65%)

BP BP
$28.57 /

+1.005 (+3.65%)

CVE Cenovus Energy
$15.61 /

+0.77 (+5.19%)

BP BP
$28.57 /

+1.005 (+3.65%)

Hot Stocks
Paychex CEO: We had record breaking sales in Q1 » 18:46
09/28/22
09/28
18:46
09/28/22
18:46
PAYX

Paychex

$117.29 /

+4.01 (+3.54%)

In an interview on…

In an interview on CNBC's Mad Money, Martin Mucci said revenue retention is better than pre-pandemic. "We're not seeing a recession at at this point," he added.

ShowHide Related Items >><<
PAYX Paychex
$117.29 /

+4.01 (+3.54%)

PAYX Paychex
$117.29 /

+4.01 (+3.54%)

07/07/22 Citi
Paychex price target lowered to $125 from $145 at Citi
06/30/22 Baird
Paychex price target lowered to $130 from $142 at Baird
06/30/22 Morgan Stanley
Paychex price target lowered to $130 from $140 at Morgan Stanley
06/30/22 Cowen
Paychex price target lowered to $135 from $140 at Cowen
PAYX Paychex
$117.29 /

+4.01 (+3.54%)

PAYX Paychex
$117.29 /

+4.01 (+3.54%)

Periodicals
McDonald's owners group says company denied request for changes, CNBC says » 18:42
09/28/22
09/28
18:42
09/28/22
18:42
MCD

McDonald's

$236.93 /

+0.19 (+0.08%)

The National Franchisee…

The National Franchisee Leadership Alliance, a group that represents McDonald's owners, said that the fast food giant spurned its request to delay changes to franchising policies, including updated standards and changes to how the company evaluates possible new operators, CNBC's Kate Rogers reports, citing a letter from the alliance to owners. The letter said that McDonald's had rejected its request to make the adjustments in June 2023 instead of January 1, the author notes. Reference Link

ShowHide Related Items >><<
MCD McDonald's
$236.93 /

+0.19 (+0.08%)

MCD McDonald's
$236.93 /

+0.19 (+0.08%)

09/27/22 Citi
Citi cuts McDonald's target, opens 'negative catalyst watch'
09/22/22 Stephens
McDonald's initiated with an Overweight at Stephens
09/21/22 Piper Sandler
Piper says Beyond Meat retail declines accelerating, cuts price target
09/07/22 Bernstein
McDonald's started at Market Perform on limited upside at Bernstein
MCD McDonald's
$236.93 /

+0.19 (+0.08%)

MCD McDonald's
$236.93 /

+0.19 (+0.08%)

MCD McDonald's
$236.93 /

+0.19 (+0.08%)

MCD McDonald's
$236.93 /

+0.19 (+0.08%)

Syndicate
Valneva announces global offering for about $40M in ADS » 18:41
09/28/22
09/28
18:41
09/28/22
18:41
VALN

Valneva

$11.11 /

+0.11 (+1.00%)

Goldman Sachs, Jefferies,…

Goldman Sachs, Jefferies, Guggenheim, and Bryan, Garnier & Co. acted as joint book running managers for the offering.

ShowHide Related Items >><<
VALN Valneva
$11.11 /

+0.11 (+1.00%)

VALN Valneva
$11.11 /

+0.11 (+1.00%)

09/23/22 Goldman Sachs
Valneva downgraded to Neutral from Buy at Goldman Sachs
08/19/22 H.C. Wainwright
Valneva price target lowered to $32 from $34 at H.C. Wainwright
08/03/22 H.C. Wainwright
Valneva initiated with a Buy at H.C. Wainwright
07/28/22 Kepler Cheuvreux
Valneva downgraded on lower COVID vaccine orders at Kepler Cheuvreux
  • 29
    Oct
VALN Valneva
$11.11 /

+0.11 (+1.00%)

Conference/Events
Kura Oncology management to meet with Cantor Fitzgerald » 18:25
09/28/22
09/28
18:25
09/28/22
18:25
KURA

Kura Oncology

$13.42 /

+0.71 (+5.59%)

In conjunction with the…

In conjunction with the Cantor Oncology, Hematology & HemeOnc Conference, Cantor Fitzgerald Biotechnology Analyst Watsek holds an Investor Group Dinner with President & CEO Wilson and SVP DeSpain in New York on September 28 at 6:30 pm hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
KURA Kura Oncology
$13.42 /

+0.71 (+5.59%)

KURA Kura Oncology
$13.42 /

+0.71 (+5.59%)

07/12/22 Cantor Fitzgerald
Kura Oncology initiated with an Overweight at Cantor Fitzgerald
07/12/22 Cantor Fitzgerald
Kura Oncology initiated with an Overweight at Cantor Fitzgerald
02/15/22 Jefferies
Kura Oncology initiated with a Buy at Jefferies
11/26/21 Credit Suisse
Kura Oncology price target lowered to $21 from $40 at Credit Suisse
KURA Kura Oncology
$13.42 /

+0.71 (+5.59%)

KURA Kura Oncology
$13.42 /

+0.71 (+5.59%)

Hot Stocks
Amazon.com expands pay, benefits for U.S. front-line employees » 18:22
09/28/22
09/28
18:22
09/28/22
18:22
AMZN

Amazon.com

$117.95 /

+3.53 (+3.09%)

Amazon announced pay…

Amazon announced pay increases for its U.S. front-line employees, a nearly $1B investment over the next year, along with a new benefit that enables employees to collect their pay at any point during the month. Average starting pay for front-line employees in customer fulfillment and transportation is increasing from $18 per hour to more than $19 per hour, with employees earning between $16 and $26 per hour depending on their position and location in the U.S. The company also announced additional investments in career development programs, building on its commitment to provide free college tuition to hourly employees. This brings the company's total investment in benefits offered to its team to nearly $10B this year alone. To prioritize flexibility and make access to pay as easy, instant, and convenient as possible for employees, Amazon expanded its pay access program, Anytime Pay, to all employees across its U.S. operations, corporate and technology networks. Anytime Pay provides Amazon employees access to up to 70% of their eligible earned pay-whenever they choose and without fees-with the goal of putting employees in control of their pay schedule. Previously, most Amazon employees received their regular pay once or twice monthly. Anytime Pay now offers employees access to their earned pay as often as they like. Building on the commitment to create career advancement opportunities for 300,000 employees through 2025, Amazon has formally added an additional development program, Amazon Intelligence Initiative. This career advancement program is designed to place employees in engineering roles within Amazon Web Services, working to operate AWS's Dedicated Cloud regions. Employees participate in a 12- to 14-month development program to enhance their technical skills. These engineers then complete multiple on the job rotations with hands-on experience alongside top AWS engineers. The Amazon Intelligence Initiative provides participants with full-time employment during this training, with great pay and benefits. Once their time in the program is completed, employees are placed into the most appropriate roles.

ShowHide Related Items >><<
AMZN Amazon.com
$117.95 /

+3.53 (+3.09%)

AMZN Amazon.com
$117.95 /

+3.53 (+3.09%)

09/28/22 Truist
Truist starts 'diversified mobility powerhouse' Rivian Automotive at Buy
09/28/22 Truist
Amazon.com price target lowered to $170 from $180 at Truist
09/26/22 Canaccord
Pay with Venmo launch on Amazon next catalyst for PayPal, says Canaccord
09/22/22 Northland
Amazon TNF kickoff scores 'a win' for Edgio, says Northland
AMZN Amazon.com
$117.95 /

+3.53 (+3.09%)

AMZN Amazon.com
$117.95 /

+3.53 (+3.09%)

AMZN Amazon.com
$117.95 /

+3.53 (+3.09%)

AMZN Amazon.com
$117.95 /

+3.53 (+3.09%)

Downgrade
Applied Genetic downgraded to Neutral from Buy at BTIG » 18:22
09/28/22
09/28
18:22
09/28/22
18:22
AGTC

Applied Genetic

/

+

, BIIB

Biogen

$276.59 /

+78.74 (+39.80%)

BTIG analyst Yun Zhong…

BTIG analyst Yun Zhong downgraded Applied Genetic (AGTC) to Neutral from Buy. The company has reported a stronger dataset than competitors that are developing similar AAV gene therapy programs for the same indication, and the stock is trading below cash with approximately 67.6M shares outstanding as of September 21, the analyst tells investors in a research note, also noting that Biogen's (BIIB) Alzheimer's disease data yesterday provided a strong lift for the entire biotech sector. Zhong adds however that the significant uncertainty created by the cash overhang for Applied Genetic, which has only $67.8M as of the end of Q3, suggests that a more prudent approach should be to remove the AGTC-501 program from valuation at this moment.

ShowHide Related Items >><<
BIIB Biogen
$276.59 /

+78.74 (+39.80%)

AGTC Applied Genetic
/

+

AGTC Applied Genetic
/

+

09/28/22 Chardan
Applied Genetic price target lowered to $3 from $5 at Chardan
06/28/22 H.C. Wainwright
H.C. Wainwright says Applied's AGTC-501 'remains leader' after MeiraGTx data
03/29/22 Chardan
Applied Genetic transferred with Buy rating at Chardan
02/14/22 Stifel
Stifel keeps Buy rating on Applied Genetic, lowers price target to $10
BIIB Biogen
$276.59 /

+78.74 (+39.80%)

09/28/22 Morgan Stanley
Eisai upgraded to Equal Weight at Morgan Stanley after lecanemab success
09/28/22 BofA
Prothena upgraded at BofA as Biogen data seen strengthening amyloid thesis
09/28/22 Needham
Path for Biogen's lecanemab to be 'multi-step' process, says Needham
09/28/22 RBC Capital
Biogen price target raised to $321 from $251 at RBC Capital
BIIB Biogen
$276.59 /

+78.74 (+39.80%)

  • 14
    Jul
  • 22
    Mar
BIIB Biogen
$276.59 /

+78.74 (+39.80%)

AGTC Applied Genetic
/

+

BIIB Biogen
$276.59 /

+78.74 (+39.80%)

Syndicate
Voxeljet announces proposed offering of ordinary shares » 18:16
09/28/22
09/28
18:16
09/28/22
18:16
VJET

Voxeljet

$3.85 /

+0.23 (+6.35%)

Voxeljet management board…

Voxeljet management board approved, with the consent of the supervisory board, an increase in the company's registered share capital against cash contributions, under exclusion of the subscription rights of existing shareholders, in an amount of up to EUR 2,108,013.00. In conjunction with the capital increase, the company will issue new registered ordinary shares with dividend entitlements beginning for the 2022 financial year, which will be offered in the form of American Depositary Receipts. Each ADR represents one ordinary share. The placement will take place today. The ADRs are listed on NASDAQ. A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.

ShowHide Related Items >><<
VJET Voxeljet
$3.85 /

+0.23 (+6.35%)

VJET Voxeljet
$3.85 /

+0.23 (+6.35%)

08/19/22 Alliance Global Partners
Voxeljet price target raised to $10 from $9 at Alliance Global Partners
05/20/22 Alliance Global Partners
Voxeljet price target lowered to $9 from $15 at Alliance Global Partners
11/12/21 Alliance Global Partners
Voxeljet price target lowered to $15 from $22 at Alliance Global Partners
VJET Voxeljet
$3.85 /

+0.23 (+6.35%)

VJET Voxeljet
$3.85 /

+0.23 (+6.35%)

Hot Stocks
Vail Resorts sees FY23 reported EBITDA $890M-$950M vs. $833M in FY22 » 18:04
09/28/22
09/28
18:04
09/28/22
18:04
MTN

Vail Resorts

$209.78 /

+6.13 (+3.01%)

Sees FY23 net income…

Sees FY23 net income $321M-$396M vs. $347.9M in FY22. The company states: "As we head into fiscal year 2023, we are encouraged by the strength in advance commitment product sales and our continued focus on enhancing the guest and employee experience while maintaining cost discipline. Our employee investment of approximately $175 million to return to full staffing levels and operational footprints, along with our expected capital investment of over $300 million in calendar year 2022, are expected to further elevate the guest experience this season and increase the capacity of our resorts. Despite facing broad cost inflation and after incorporating our industry-leading wage investment, we expect meaningful growth for fiscal 2023 relative to fiscal 2022 and strong Resort EBITDA margin. Our guidance for net income attributable to Vail Resorts, Inc. is estimated to be between $321 million and $396 million for fiscal 2023. We estimate Resort Reported EBITDA for fiscal 2023 will be between $893 million and $947 million. We expect the operations of the Seven Springs Resorts and Andermatt-Sedrun to contribute approximately $22 million of Resort Reported EBITDA in fiscal year 2023, which is an incremental $4 million of Resort Reported EBITDA compared to fiscal year 2022, excluding acquisition and integration related expenses. Acquisition and integration related expenses are expected to be an estimated $4 million in fiscal year 2023 associated with the resort acquisitions. We estimate Resort EBITDA Margin for fiscal 2023 to be approximately 31.0% using the midpoint of the guidance range."

ShowHide Related Items >><<
MTN Vail Resorts
$209.78 /

+6.13 (+3.01%)

MTN Vail Resorts
$209.78 /

+6.13 (+3.01%)

09/26/22 Stifel
Vail Resorts price target lowered to $228 from $273 at Stifel
06/28/22 Barclays
Barclays says shift in preferences to cushion Gaming, Cruises, Timeshare names
06/28/22 Barclays
Vail Resorts initiated with an Underweight at Barclays
06/10/22 Truist
Vail Resorts price target raised to $281 from $278 at Truist
MTN Vail Resorts
$209.78 /

+6.13 (+3.01%)

MTN Vail Resorts
$209.78 /

+6.13 (+3.01%)

Earnings
Enerpac Tool sees FY23 revenue $565M-$585M, consensus $597.8M » 18:03
09/28/22
09/28
18:03
09/28/22
18:03
EPAC

Enerpac Tool

$16.83 /

+0.57 (+3.51%)

Sees FY23 adjusted EBITDA…

Sees FY23 adjusted EBITDA $113M-$123M, including an ASCEND EBITDA benefit of $12M-$18M.

ShowHide Related Items >><<
EPAC Enerpac Tool
$16.83 /

+0.57 (+3.51%)

EPAC Enerpac Tool
$16.83 /

+0.57 (+3.51%)

06/22/22 Wells Fargo
Wells Fargo upgrades Enerpac Tool to Overweight, raises price target to $23
06/22/22 Wells Fargo
Enerpac Tool upgraded to Overweight from Equal Weight at Wells Fargo
01/07/22 JPMorgan
Enerpac Tool upgraded to Neutral at JPMorgan after underperformance
01/07/22 JPMorgan
Enerpac Tool upgraded to Neutral from Underweight at JPMorgan
EPAC Enerpac Tool
$16.83 /

+0.57 (+3.51%)

EPAC Enerpac Tool
$16.83 /

+0.57 (+3.51%)

Earnings
Enerpac Tool reports Q4 adjusted EPS 37c vs. 19c a year ago » 18:01
09/28/22
09/28
18:01
09/28/22
18:01
EPAC

Enerpac Tool

$16.83 /

+0.57 (+3.51%)

Reports Q4 revenue…

Reports Q4 revenue $151.8M vs. $145.4M a year ago. "We exited fiscal 2022 with increased demand in both our product and service businesses, as well as solid core sales growth in two of our four regions," said Paul Sternlieb, Enerpac Tool Group's President & CEO. "We are pleased with our team's performance in the quarter and the momentum that we are building, despite the continued difficult macroeconomic environment and ongoing supply chain challenges." Sternlieb continued, "During the fourth quarter, we delivered on our topline, adjusted EBITDA and cash flow initiatives across the Company, and we broke the typical fourth quarter seasonal sales trend, with sequential growth over the third quarter on a constant currency basis. At the same time, we continued to make important progress on our ASCEND transformation program, with an emphasis on delivering profitable growth as we move into fiscal 2023 and beyond. Our strong cash flow and adjusted EBITDA performance in the quarter allowed us to continue to deploy capital through share repurchase, consistent with our capital allocation strategy, and reduce our leverage ratio."

ShowHide Related Items >><<
EPAC Enerpac Tool
$16.83 /

+0.57 (+3.51%)

EPAC Enerpac Tool
$16.83 /

+0.57 (+3.51%)

06/22/22 Wells Fargo
Wells Fargo upgrades Enerpac Tool to Overweight, raises price target to $23
06/22/22 Wells Fargo
Enerpac Tool upgraded to Overweight from Equal Weight at Wells Fargo
01/07/22 JPMorgan
Enerpac Tool upgraded to Neutral at JPMorgan after underperformance
01/07/22 JPMorgan
Enerpac Tool upgraded to Neutral from Underweight at JPMorgan
EPAC Enerpac Tool
$16.83 /

+0.57 (+3.51%)

EPAC Enerpac Tool
$16.83 /

+0.57 (+3.51%)

On The Fly
Fly Intel: After-Hours Movers » 17:59
09/28/22
09/28
17:59
09/28/22
17:59
MTN

Vail Resorts

$209.78 /

+6.13 (+3.01%)

, MOR

MorphoSys

$5.50 /

+0.99 (+21.95%)

, FSLR

First Solar

$136.22 /

+3.845 (+2.90%)

, AMPS

Altus Power

$14.23 /

+0.34 (+2.45%)

, ADC

Agree Realty

$69.17 /

+1.04 (+1.53%)

Check out this evening's…

ShowHide Related Items >><<
MTN Vail Resorts
$209.78 /

+6.13 (+3.01%)

MOR MorphoSys
$5.50 /

+0.99 (+21.95%)

FSLR First Solar
$136.22 /

+3.845 (+2.90%)

AMPS Altus Power
$14.23 /

+0.34 (+2.45%)

ADC Agree Realty
$69.17 /

+1.04 (+1.53%)

MTN Vail Resorts
$209.78 /

+6.13 (+3.01%)

09/26/22 Stifel
Vail Resorts price target lowered to $228 from $273 at Stifel
06/28/22 Barclays
Barclays says shift in preferences to cushion Gaming, Cruises, Timeshare names
06/28/22 Barclays
Vail Resorts initiated with an Underweight at Barclays
06/10/22 Truist
Vail Resorts price target raised to $281 from $278 at Truist
MOR MorphoSys
$5.50 /

+0.99 (+21.95%)

09/06/22 Morgan Stanley
Biogen named a 'Catalyst Driven Idea' at Morgan Stanley
08/10/22 JPMorgan
MorphoSys price target lowered to EUR 32.50 from EUR 34 at JPMorgan
07/29/22 Morgan Stanley
MorphoSys price target raised to EUR 28 from EUR 26 at Morgan Stanley
06/24/22 Morgan Stanley
MorphoSys price target lowered to EUR 26 from EUR 37 at Morgan Stanley
FSLR First Solar
$136.22 /

+3.845 (+2.90%)

09/28/22 Evercore ISI
First Solar upgraded to Outperform at Evercore ISI on IRA benefits
09/28/22 Evercore ISI
First Solar upgraded to Outperform from In Line at Evercore ISI
09/09/22 Susquehanna
First Solar price target raised to $175 from $120 at Susquehanna
09/07/22 Goldman Sachs
First Solar upgraded to Buy from Sell at Goldman Sachs
AMPS Altus Power
$14.23 /

+0.34 (+2.45%)

08/18/22 Morgan Stanley
Altus Power price target raised to $12.50 from $10 at Morgan Stanley
08/08/22 JPMorgan
Altus Power price target raised to $11 from $9 at JPMorgan
07/18/22 JPMorgan
Altus Power initiated with a Neutral at JPMorgan
06/15/22 Citi
Citi still likes Altus Power in current environment
ADC Agree Realty
$69.17 /

+1.04 (+1.53%)

08/22/22 Truist
Agree Realty price target raised to $84 from $77 at Truist
08/04/22 RBC Capital
Agree Realty price target raised to $83 from $76 at RBC Capital
06/30/22 Jefferies
Agree Realty price target raised to $82 from $80 at Jefferies
06/22/22 Credit Suisse
Agree Realty initiated with an Outperform at Credit Suisse
MTN Vail Resorts
$209.78 /

+6.13 (+3.01%)

FSLR First Solar
$136.22 /

+3.845 (+2.90%)

AMPS Altus Power
$14.23 /

+0.34 (+2.45%)

ADC Agree Realty
$69.17 /

+1.04 (+1.53%)

  • 29
    Sep
  • 29
    Sep
  • 26
    May
  • 09
    Dec
FSLR First Solar
$136.22 /

+3.845 (+2.90%)

MTN Vail Resorts
$209.78 /

+6.13 (+3.01%)

MOR MorphoSys
$5.50 /

+0.99 (+21.95%)

FSLR First Solar
$136.22 /

+3.845 (+2.90%)

ADC Agree Realty
$69.17 /

+1.04 (+1.53%)

FSLR First Solar
$136.22 /

+3.845 (+2.90%)

Hot Stocks
Sony's PlayStation Stars loyalty program launches in Asia » 17:59
09/28/22
09/28
17:59
09/28/22
17:59
SONY

Sony

$66.94 /

+1.03 (+1.56%)

Sony's PlayStation…

Sony's PlayStation said it has launched its new loyalty program, PlayStation Stars, in Asia on Wednesday. The company will roll out the service in North and South America on October 5 and Europe and Australia on October 13. "With this launch, we commence our global rollout for PlayStation Stars, and this is just the beginning," the company said. We will continue to evolve the program by adding new features, rewards, benefits and ways to enjoy what you love about PlayStation." Reference Link

ShowHide Related Items >><<
SONY Sony
$66.94 /

+1.03 (+1.56%)

SONY Sony
$66.94 /

+1.03 (+1.56%)

09/07/22 Goldman Sachs
Sony resumed with a Neutral at Goldman Sachs
07/08/22 Macquarie
Sony upgraded to Outperform, added to 'Marquee Buy' list at Macquarie
07/05/22 Citi
Sony downgraded to Neutral from Buy at Citi
05/18/22 Oppenheimer
Sony price target lowered to $125 from $150 at Oppenheimer
SONY Sony
$66.94 /

+1.03 (+1.56%)

SONY Sony
$66.94 /

+1.03 (+1.56%)

SONY Sony
$66.94 /

+1.03 (+1.56%)

Conference/Events
Kura Oncology management to meet with Cantor Fitzgerald » 17:55
09/28/22
09/28
17:55
09/28/22
17:55
KURA

Kura Oncology

$13.42 /

+0.71 (+5.59%)

In conjunction with the…

In conjunction with the Cantor Oncology, Hematology & HemeOnc Conference, Cantor Fitzgerald Biotechnology Analyst Watsek holds an Investor Group Dinner with President & CEO Wilson and SVP DeSpain in New York on September 28 at 6:30 pm hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
KURA Kura Oncology
$13.42 /

+0.71 (+5.59%)

KURA Kura Oncology
$13.42 /

+0.71 (+5.59%)

07/12/22 Cantor Fitzgerald
Kura Oncology initiated with an Overweight at Cantor Fitzgerald
07/12/22 Cantor Fitzgerald
Kura Oncology initiated with an Overweight at Cantor Fitzgerald
02/15/22 Jefferies
Kura Oncology initiated with a Buy at Jefferies
11/26/21 Credit Suisse
Kura Oncology price target lowered to $21 from $40 at Credit Suisse
KURA Kura Oncology
$13.42 /

+0.71 (+5.59%)

KURA Kura Oncology
$13.42 /

+0.71 (+5.59%)

Periodicals
Chevron sells global headquarters in California, WSJ reports » 17:45
09/28/22
09/28
17:45
09/28/22
17:45
CVX

Chevron

$145.70 /

+4.79 (+3.40%)

Chevron has sold its…

Chevron has sold its global headquarters in California and plans to move into a nearby leased space about one-third of the size, as it continues to relocate employees to Texas, The Wall Street Journal's Collin Eaton reports. Reference Link

ShowHide Related Items >><<
CVX Chevron
$145.70 /

+4.79 (+3.40%)

CVX Chevron
$145.70 /

+4.79 (+3.40%)

09/12/22 Piper Sandler
Chevron price target raised to $190 from $189 at Piper Sandler
09/06/22 Morgan Stanley
Chevron price target raised to $193 from $187 at Morgan Stanley
08/22/22 BMO Capital
Chevron execution to remain strong, says BMO Capital
08/15/22 Cowen
Chevron price target raised to $120 from $119 at Cowen
CVX Chevron
$145.70 /

+4.79 (+3.40%)

CVX Chevron
$145.70 /

+4.79 (+3.40%)

CVX Chevron
$145.70 /

+4.79 (+3.40%)

CVX Chevron
$145.70 /

+4.79 (+3.40%)

Hot Stocks
Regeneron, Sanofi announce FDA approval of Dupixent » 17:45
09/28/22
09/28
17:45
09/28/22
17:45
REGN

Regeneron

$705.42 /

+10.45 (+1.50%)

, SNY

Sanofi

$38.17 /

+0.935 (+2.51%)

Regeneron (REGN) and…

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has approved Dupixent for the treatment of adult patients with prurigo nodularis. With this approval, Dupixent becomes the first and only medicine specifically indicated to treat prurigo nodularis in the U.S. Prurigo nodularis is a chronic, debilitating skin disease with underlying type 2 inflammation and its impact on quality of life is one of the highest among inflammatory skin diseases. The FDA evaluated the Dupixent application for prurigo nodularis under priority review, which is granted to therapies that have the potential to provide significant improvements in the treatment, diagnosis or prevention of serious conditions.

ShowHide Related Items >><<
SNY Sanofi
$38.17 /

+0.935 (+2.51%)

REGN Regeneron
$705.42 /

+10.45 (+1.50%)

REGN Regeneron
$705.42 /

+10.45 (+1.50%)

09/16/22 Canaccord
Regeneron price target raised to $750 from $700 at Canaccord
09/13/22 Piper Sandler
Regeneron price target raised to $775 from $692 at Piper Sandler
09/12/22 Piper Sandler
Regeneron data at ESMO showcases 'power' of oncology pipeline, says Piper
09/12/22 Guggenheim
Regeneron price target raised to $925 from $740 at Guggenheim
SNY Sanofi
$38.17 /

+0.935 (+2.51%)

09/15/22 Credit Suisse
Sanofi price target lowered to EUR 106 from EUR 110 at Credit Suisse
09/07/22 Deutsche Bank
Sanofi price target lowered to EUR 85 from EUR 90 at Deutsche Bank
09/07/22 Morgan Stanley
Sanofi price target lowered to EUR 93 from EUR 112 at Morgan Stanley
08/26/22 Citi
Citi opens 'positive catalyst watches' on GSK, Sanofi after Zantac ruling
SNY Sanofi
$38.17 /

+0.935 (+2.51%)

REGN Regeneron
$705.42 /

+10.45 (+1.50%)

SNY Sanofi
$38.17 /

+0.935 (+2.51%)

REGN Regeneron
$705.42 /

+10.45 (+1.50%)

SNY Sanofi
$38.17 /

+0.935 (+2.51%)

REGN Regeneron
$705.42 /

+10.45 (+1.50%)

SNY Sanofi
$38.17 /

+0.935 (+2.51%)

REGN Regeneron
$705.42 /

+10.45 (+1.50%)

Syndicate
Momentus launches 3-year $50M at-the-market equity program » 17:39
09/28/22
09/28
17:39
09/28/22
17:39
MNTS

Momentus

$1.50 /

+0.1 (+7.14%)

Momentus "announces…

Momentus "announces that it has entered into an equity distribution agreement, providing for an at-the-market equity offering program. Pursuant to the ATM Program, Momentus may, at its discretion and from time to time during the three-year term of the Distribution Agreement, offer and sell such number of Class A shares of its common stock as would result in aggregate gross proceeds to Momentus of up to $50 million. The shares will be offered through Stifel, Nicolaus & Company."

ShowHide Related Items >><<
MNTS Momentus
$1.50 /

+0.1 (+7.14%)

MNTS Momentus
$1.50 /

+0.1 (+7.14%)

07/05/22 Evercore ISI
Momentus initiated with an Underperform at Evercore ISI
05/23/22 Deutsche Bank
Momentus named short-term buy idea at Deutsche Bank
05/11/22 Deutsche Bank
Momentus price target lowered to $7 from $8 at Deutsche Bank
03/23/22 Deutsche Bank
SpaceX decision 'clear positive' for Momentus, says Deutsche Bank
MNTS Momentus
$1.50 /

+0.1 (+7.14%)

MNTS Momentus
$1.50 /

+0.1 (+7.14%)

Earnings
Volta withdraws FY22 revenue guidance  17:38
09/28/22
09/28
17:38
09/28/22
17:38
VLTA

Volta

$1.57 /

+0.055 (+3.64%)

 
ShowHide Related Items >><<
VLTA Volta
$1.57 /

+0.055 (+3.64%)

VLTA Volta
$1.57 /

+0.055 (+3.64%)

08/09/22 Roth Capital
Volta downgraded to Neutral from Buy at Roth Capital
08/04/22 Barclays
Volta initiated with an Equal Weight at Barclays
06/13/22 Cantor Fitzgerald
Volta downgraded to Neutral at Cantor Fitzgerald as CFO departs
06/13/22 Cantor Fitzgerald
Volta downgraded to Neutral from Overweight at Cantor Fitzgerald
VLTA Volta
$1.57 /

+0.055 (+3.64%)

VLTA Volta
$1.57 /

+0.055 (+3.64%)

VLTA Volta
$1.57 /

+0.055 (+3.64%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.